{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:00:27Z","timestamp":1787763627962,"version":"build-2784847793"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Anticoagulation is the mainstay of stroke prevention in appropriate patients with atrial fibrillation. Due to advances in pharmacotherapy the anticoagulants used for this purpose have evolved significantly over the past decades with the aim of optimizing effectiveness while minimizing bleeding risks. Though significant improvements have been made toward this goal, bleeding risk remains the major concern with these therapies. An investigational class of agents which inhibit Factor XI have shown promise in pre-clinical and early clinical trials to significantly minimize bleeding while maintaining efficacy against stroke and systemic embolism. This mini-review will discuss anticoagulants currently used for stroke prevention in patients with atrial fibrillation including warfarin and direct oral anticoagulants. We will also review the mechanism of action and data from early clinical trials for Factor XI inhibitors and discuss their potential advantages and shortcomings.<\/jats:p>","DOI":"10.3389\/fcvm.2024.1352734","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T04:44:05Z","timestamp":1707108245000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors"],"prefix":"10.3389","volume":"11","author":[{"given":"Vineet","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Ilkhanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1001\/jama.2015.4369","article-title":"Stroke prevention in atrial fibrillation: a systematic review","volume":"313","author":"Lip","year":"2015","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2023","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s11886-022-01787-1","article-title":"Stroke prevention in atrial fibrillation","volume":"24","author":"Gao","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/a-1384-3715","article-title":"Factor XI as a target for new anticoagulants","volume":"41","author":"Fredenburgh","year":"2021","journal-title":"Hamostaseologie"},{"key":"B12","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1080\/14656566.2022.2149323","article-title":"Pharmacology for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions","volume":"23","author":"Gomez-Outes","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehac464","article-title":"Factor XI inhibitors: cardiovascular perspectives","volume":"44","author":"De Caterina","year":"2023","journal-title":"Eur Heart J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1055\/a-1984-7021","article-title":"A review of FXIa inhibition as a novel target for anticoagulation","volume":"43","author":"Koulas","year":"2023","journal-title":"Hamostaseologie"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/bab.2028","article-title":"Antisense oligonucleotide (AS-ODN) technology: principle, mechanism, and challenges","volume":"68","author":"Gheibi-Hayat","year":"2021","journal-title":"Biotechnol Appl Biochem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s13311-023-01423-y","article-title":"Evolving therapeutic options for the treatment of duchenne muscular dystrophy","volume":"147","author":"Ambrosio","year":"2023","journal-title":"Neurotherapeutics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: a double-edged sword?","volume":"9","author":"Ramos-Casals","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/FJC.0000000000000921","article-title":"Osocimab: a novel agent in preventing venous thromboembolism","volume":"76","author":"Beavers","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rth2.12509","article-title":"Antithrombotics and new interventions for venous thromboembolism: exploring possibilities beyond factor IIa and factor Xa inhibition","volume":"5","author":"Mavromanoli","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1055\/a-2061-3311","article-title":"Antithrombotic effects of the novel small-molecule factor XIa inhibitor milvexian in a rabbit arteriovenous shunt model of venous thrombosis","volume":"7","author":"Wang","year":"2023","journal-title":"TH Open"},{"key":"B24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1352734\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T16:16:46Z","timestamp":1713284206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1352734\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":24,"alternative-id":["10.3389\/fcvm.2024.1352734"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1352734","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]},"article-number":"1352734"}}